A study to determine pharmacokinetics and pharmacodynamics of MORF-057 and multidose assessment to 200 mg BID single and twice daily dosing in healthy subjects
Latest Information Update: 23 Dec 2022
At a glance
- Drugs MORF 057 (Primary)
- Indications Crohn's disease; Ulcerative proctitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 23 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022